Madhuri Chandnani

Madhuri Chandnani

Auto-generated profile, based on publicly available information

Madhuri Chandnani

Bombay Hospital and Medical Research Center

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
TETarec K. Elajami
Tarec K. Elajami
AAAbdulhamied Alfaddagh
Abdulhamied Alfaddagh
DLDharshan Lakshminarayan
Dharshan Lakshminarayan
MSMichael Soliman
Michael Soliman
MCMadhuri Chandnani
Madhuri Chandnani
FWFrancine K. Welty
Francine K. Welty
Background: Albuminuria is a marker of inflammation and an independent predictor of cardiovascular morbidity and mortality. The current study evaluated whether eicosapentaenoic acid ( EPA ) and docosahexaenoic acid ( DHA ) supplementation attenuates progression of albuminuria in subjects with coronary artery disease. Methods and Results: Two‐hundred sixty‐two subjects with stable coronary artery disease were randomized to either Lovaza (1.86 g of EPA and 1.5 g of DHA daily) or no Lovaza (control) for 1 year. Percent change in urine albumin‐to‐creatinine ratio ( ACR ) was compared. Mean ( SD ) age was 63.3 (7.6) years; 17% were women and 30% had type 2 diabetes mellitus. In nondiabetic subjects, no change in urine ACR occurred in either the Lovaza or control groups. In contrast, ACR increased 72.3% ( P <0.001) in diabetic subjects not receiving Lovaza, whereas those receiving Lovaza had no change. In diabetic subjects on an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker, those receiving Lovaza had no change in urine ACR , whereas those not receiving Lovaza had a 64.2% increase ( P <0.001). Change in ACR was directly correlated with change in systolic blood pressure ( r =0.394, P =0.01). Conclusions: EPA and DHA supplementation attenuated progression of albuminuria in subjects with type 2 diabetes mellitus and coronary artery disease, most of whom were on an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker. Thus, EPA and DHA supplementation should be considered as additional therapy to an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker in subjects with type 2 diabetes mellitus and coronary artery disease. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01624727.

1 September 2015 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
ASApurva S Shah
Apurva S Shah
DADeepak Amarapurkar
Deepak Amarapurkar
MDMrudul Dharod
Mrudul Dharod
MCMadhuri Chandnani
Madhuri Chandnani
RBRajiv Baijal
Rajiv Baijal
SDSoham Doshi
Soham Doshi

1 June 2014 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
RBRajiv Baijal
Rajiv Baijal
DADeepak Amarapurkar
Deepak Amarapurkar
HKH. R. Praveen Kumar
H. R. Praveen Kumar
SKSandeep Kulkarni
Sandeep Kulkarni
NSNimish Shah
Nimish Shah
SGSonali Gautam
Sonali Gautam

1 May 2015 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
DADeepak Amarapurkar
Deepak Amarapurkar
MDMrudul V Dharod
Mrudul V Dharod
MCMadhuri Chandnani
Madhuri Chandnani
RBRajiv Baijal
Rajiv Baijal
PKPraveen Kumar
Praveen Kumar
SDSoham Doshi
Soham Doshi

25 September 2018 in Case Reports in Gastrointestinal Medicine
Verified
Journal Article
Open access
PDF file
MCMadhuri Chandnani
Madhuri Chandnani
JCJonah Cohen
Jonah Cohen
TBTyler M. Berzin
Tyler M. Berzin
Self-expanding removable stents are used for the treatment of esophageal strictures. Partially covered metal stents become embedded in the esophageal wall due to mucosal tissue reaction providing good anchorage. This can also lead to extreme difficulty in the removal of such stents. Several different individual techniques have been used in literature for removal of these esophageal stents. Ours is the first case using a combination of cryoablation and stent-in-stent technique for removal of an extremely difficult case of embedded esophageal stent.

16 August 2016 in American Journal of Case Reports
Verified
Journal Article
Open access
PDF file
MCMadhuri Chandnani
Madhuri Chandnani
MKMandeep Kaur
Mandeep Kaur
ARAnusha Ramadhas
Anusha Ramadhas
TTTaisiya Tumarinson
Taisiya Tumarinson
BACKGROUND:Hepatitis E virus (HEV) is the most common cause of enterically acquired acute viral hepatitis worldwide with major prevalence in the developing countries. An increasing number of sporadic cases of acute HEV infection have also been found ...